
 
													 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Odevixibat
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Health Canada Approves Bylvay for the Treatment of Cholestatic Pruritus
Details : Bylvay (odevixibat) is an Ileal bile acid transporter inhibitor indicated for the treatment of cholestatic pruritus in patients with alagille syndrome.
Product Name : Bylvay
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 09, 2025
Lead Product(s) : Odevixibat
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Patisiran
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Alnylam Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Medison and Alnylam Expand RNAi Therapeutics Partnership in Europe, Israel, and LATAM/APAC
Details : Alnylam's collaboration with Medison leverages Medison’s multi-regional platform to make RNAi therapeutics like ONPATTRO, GIVLAARI, and OXLUMO available in LATAM, APAC, and additional global markets.
Product Name : Onpattro
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
April 30, 2024
Lead Product(s) : Patisiran
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Alnylam Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cemiplimab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Medison Pharma Partners with Regeneron to Commercialize Libtayo® Globally
Details : Medison will commercialize Libtayo (cemiplimab), an anti-PD-1 monoclonal antibody, in select European and global markets under a new agreement.
Product Name : Libtayo
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
January 08, 2024
Lead Product(s) : Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Givosiran Sodium
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Alnylam Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Details : The new agreement will allow Alnylam to utilize Medison's unique multi-regional platform to ensure that Alnylam's innovative RNAi therapeutics, such as ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran) are made available across additiona...
Product Name : Givlaari
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
March 09, 2023
Lead Product(s) : Givosiran Sodium
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Alnylam Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Expanded Collaboration

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tebentafusp
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Immunocore
Deal Size : Undisclosed
Deal Type : Agreement
Details : Kimmtrak (tebentafusp) is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. Tebentafusp specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma.
Product Name : Kimmtrak
Product Type : Protein
Upfront Cash : Undisclosed
November 09, 2022
Lead Product(s) : Tebentafusp
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Immunocore
Deal Size : Undisclosed
Deal Type : Agreement

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Imlifidase
Therapeutic Area : Immunology
Study Phase : Approved FDF
Recipient : Hansa Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Idefirix® (imlifidase) becomes the first and only product reimbursed for the desensitization of highly sensitized patients waiting for a kidney transplant in Poland.
Product Name : Idefirix
Product Type : Enzyme
Upfront Cash : Inapplicable
August 22, 2022
Lead Product(s) : Imlifidase
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Recipient : Hansa Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Odevixibat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Approved FDF
Sponsor : Albireo Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the agreement with Albireo, Medison aims to commercialize Odevixibat in Canada and Israel, for the treatment of patients with cholestatic liver diseases. Odevixibat is approved in Europe as Bylvay® for the treatment of progressive familial intrahe...
Product Name : Bylvay
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 16, 2022
Lead Product(s) : Odevixibat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved FDF
Sponsor : Albireo Pharma
Deal Size : Undisclosed
Deal Type : Partnership

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Efgartigimod Alpha
Therapeutic Area : Immunology
Study Phase : Approved FDF
Recipient : Argenx
Deal Size : Undisclosed
Deal Type : Partnership
Details : Efgartigimod is approved in the United States as VYVGART® for the treatment of adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and in Japan for the treatment of adults with gMG.
Product Name : Vyvgart
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
June 06, 2022
Lead Product(s) : Efgartigimod Alpha
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Recipient : Argenx
Deal Size : Undisclosed
Deal Type : Partnership

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tebentafusp
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Immunocore
Deal Size : Undisclosed
Deal Type : Agreement
Details : The multi-territorial agreement to help seek regulatory authorization and commercialize Immunocore's KIMMTRAK® (tebentafusp -tebn) for the treatment of unresectable or metastatic uveal melanoma, a rare and aggressive form of melanoma that affects the ey...
Product Name : Kimmtrak
Product Type : Protein
Upfront Cash : Undisclosed
May 23, 2022
Lead Product(s) : Tebentafusp
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Immunocore
Deal Size : Undisclosed
Deal Type : Agreement

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zanubrutinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : BeOne Medicines
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BRUKINSA is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) discovered by BeiGene scientists that is currently being evaluated globally in a broad clinical program as a monotherapy and in combination with other therapies to treat various B...
Product Name : Brukinsa
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 15, 2022
Lead Product(s) : Zanubrutinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : BeOne Medicines
Deal Size : Inapplicable
Deal Type : Inapplicable

 Reset All
Reset All